Quality of Life in Postmenopausal Patients with Breast Cancer after Failure of Tamoxifen: Formestane Versus Megestrol Acetate as Second-line Hormonal Treatment

By Bernhard J.   Castiglione-Gertsch M.   Schmitz S.-F.H.   Thurlimann B.   Cavalli F.   Morant R.   Fey M.F.   Bonnefoi H.   Goldhirsch A.   Hurny C.  

European Journal of Cancer, Vol. 35, Iss. 6, 1999-06 ,pp. : 913-920

Elsevier

Access to resources Recommend Favorite

Tamoxifen for one year versus two years versus 6 months of Tamoxifen and 6 months of megestrol acetate: A randomized comparison in postmenopausal patients with high-risk breast cancer (DBCG 89C)

By Andersen Jørn   Kamby Claus   Ejlertsen Bent   Cold Søren   Ewertz Marianne   Jacobsen Erik   Philip Preben   Møller Knud   Jensen Disa   Møller Susanne  

Acta Oncologica, Vol. 47, Iss. 4, 2008-01 ,pp. : 718-724

Informa Healthcare

Access to resources Recommend Favorite

Formestane Versus Megestrol Acetate in Postmenopausal Breast Cancer Patients After Failure of Tamoxifen: a Phase III Prospective Randomised Cross Over Trial of Second-line Hormonal Treatment (SAKK 2090)

By Swiss Group for Clinical Cancer Research SAKK   Thurlimann B.   Castiglione M.   Hsu-Schmitz S.F.   Cavalli F.   Bonnefoi H.   Fey M.F.   Morant R.   Lohnert T.   Goldhirsch A.  

European Journal of Cancer, Vol. 33, Iss. 7, 1997-06 ,pp. : 1017-1024

Elsevier

Access to resources Recommend Favorite

A Randomised Phase III Cross-over Study of Tamoxifen Versus Megestrol Acetate in Advanced and Recurrent Breast Cancer

By Stuart N.S.A.   Warwick J.   Blackledge G.R.P.   Spooner D.   Keen C.   Taylor A.R.   Tyrell C.   Webster D.J.T.   Earl H.  

European Journal of Cancer, Vol. 32, Iss. 11, 1996-10 ,pp. : 1888-1892

Elsevier

Access to resources Recommend Favorite

Estrogenic Effects of Toremifene and Tamoxifen in Postmenopausal Breast Cancer Patients

By Ellmén J.  

Breast Cancer Research and Treatment, Vol. 82, Iss. 2, 2003-01 ,pp. : 103-111

Springer Publishing Company

Access to resources Recommend Favorite